TSLA
Tesla
-- 355.840 NVDA
NVIDIA
-- 138.850 INTC
Intel
-- 23.600 NBIS
NEBIUS
-- 44.490 PLTR
Palantir
-- 119.160 
NEWS
VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies
Cryoport, Inc. (NASDAQ: CYRX) and VGXI, Inc. have announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments. The collaboration will commence in October 2024, with Cryoport Systems providing biostorage and bioservices from its Houston, Texas facility for plasmid DNA products manufactured at VGXI's facilities in The Woodlands and Conroe, Texas.
This partnership combines VGXI's expertise in plasmid DNA manufacturing with Cryoport's integrated supply chain solutions, including shipping services, data solutions, and comprehensive support services. The collaboration aims to enhance support for biopharmaceutical companies developing next-generation therapies, ensuring seamless final delivery to VGXI's end customers.
This partnership combines VGXI's expertise in plasmid DNA manufacturing with Cryoport's integrated supply chain solutions, including shipping services, data solutions, and comprehensive support services. The collaboration aims to enhance support for biopharmaceutical companies developing next-generation therapies, ensuring seamless final delivery to VGXI's end customers.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8160
Followers
50
Following
93K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call